NCT04930783View on ClinicalTrials.gov

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

September 30, 2030

Conditions
MelanomaMetastatic Melanoma
Interventions
DRUG

CDX-301

Administered as an injection given underneath the skin

BIOLOGICAL

NEOVAX

Personalized neoantigen vaccine administered as an injection given underneath the skin

DRUG

Nivolumab

Administered intravenously (IV)

DRUG

Pembrolizumab

Administered intravenously (IV)

Trial Locations (1)

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Celldex Therapeutics
All Listed Sponsors
collaborator

Celldex Therapeutics

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT04930783 - NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | Biotech Hunter | Biotech Hunter